{"id":5902,"date":"2024-12-04T15:03:40","date_gmt":"2024-12-04T14:03:40","guid":{"rendered":"https:\/\/crcm-marseille.fr\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/"},"modified":"2025-06-23T14:04:23","modified_gmt":"2025-06-23T12:04:23","slug":"antibody-therapeutics-and-immunotargeting","status":"publish","type":"page","link":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/","title":{"rendered":"Antibody Therapeutics and Immunotargeting"},"content":{"rendered":"\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/en\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847\" alt=\"Logo Marseille Cancer Research Center\"\/><\/a><\/figure>\n\n<ul id=\"menu-menu-principal\" class=\"wp-block-list\">\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/\">Home<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\">Our center<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\">Our research<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\">For students<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\">For scientists<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\">Research teams<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\"><\/a><\/li>\n<\/ul>\n\n<figure class=\"wp-block-image\"><a class=\"\" href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-departement-ohio-crcm-1024x622.png\" alt=\"Logo Ohio department Marseille Cancer Research Center\"\/><\/a><\/figure>\n\n<h1 class=\"wp-block-heading\">Antibody Therapeutics and Immunoblotting (ATI)<\/h1>\n\n<p>Luminy<\/p>\n\n<figure class=\"wp-block-image\"><a class=\"\" href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/#\" target=\"_blank\" rel=\"noreferrer noopener\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/09\/logo-x-equipe-crcm.png\" alt=\"\"\/><\/a><\/figure>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/patrick-chames\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/Patrick-Chames.jpg?ver=1737458253\" alt=\"Patrick Chames - Therapeutic Antibodies and Immunoblotting Team (ATI) - Single-Domain Antibody Platform - CRCM\"\/><\/a><\/figure>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/patrick-chames\/\">Patrick Chames<\/a><\/p>\n\n<p>Team manager<\/p>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/remy-boisgard\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/remy-boisgard\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/boisgard_remi_crcm.jpg\" alt=\"Boisgard R&#xE9;mi - Marseille Cancer Research Center - Antibody Therapeutics and Immunoblotting Team (ATI)\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">R\u00e9my Boisgard<\/h2>\n\n<h4 class=\"wp-block-heading\">Doctoral student<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/sarah-tazekritt\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/sarah-tazekritt\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/picto-sans-image.jpg\" alt=\"Sarah Tazekritt\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Sarah Tazekritt<\/h2>\n\n<h4 class=\"wp-block-heading\">Master 2 trainee<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/timothee-chanier\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/timothee-chanier\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/Timothee-Chanier.jpg\" alt=\"Timoth&#xE9;e Chanier - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Timoth\u00e9e Chanier<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/antonoff-octavia\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/antonoff-octavia\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/Antonoff-Octavia.jpg\" alt=\"Antonoff Octavia - Antibody Therapeutics and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Antonoff Octavia<\/h2>\n\n<h4 class=\"wp-block-heading\">Lecturer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/brigitte-kerfelec\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/brigitte-kerfelec\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/kerfelec_brigitte_crcm.jpg\" alt=\"Kerfelec Brigitte - Marseille Cancer Research Center - Therapeutic Antibodies and Immunoblotting Team (ATI)\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Brigitte Kerfelec<\/h2>\n\n<h4 class=\"wp-block-heading\">Researcher<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/celia-torrielli\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/celia-torrielli\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/torrielli_celia_crcm.jpg\" alt=\"Torrielli C&#xE9;lia - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">C\u00e9lia Torrielli<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/damien-meyer\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/damien-meyer\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/Damien-Meyer.jpg\" alt=\"Damien Mayer - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Damien Meyer<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/juliette-prothon\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/juliette-prothon\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/prothon_juliette_crcm.jpg\" alt=\"Prothon Juliette - Marseille Cancer Research Center - Antibody Therapeutics and Immunoblotting Team (ATI)\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Juliette Prothon<\/h2>\n\n<h4 class=\"wp-block-heading\">Doctoral student<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/lea-izzo\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/lea-izzo\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/Lea-Izzo.jpg\" alt=\"L&#xE9;a Izzo - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Lea Izzo<\/h2>\n\n<h4 class=\"wp-block-heading\">?<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/lisa-malard\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/lisa-malard\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/picto-sans-image.jpg\" alt=\"Lisa Malard\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Lisa Malard<\/h2>\n\n<h4 class=\"wp-block-heading\">Master 2 trainee<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/maeva-ancarola\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/maeva-ancarola\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/picto-sans-image.jpg\" alt=\"Maeva Ancarola\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Maeva Ancarola<\/h2>\n\n<h4 class=\"wp-block-heading\">Master 2 trainee<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/morgane-thepaut\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/morgane-thepaut\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/Morgane-Thepaut.jpg\" alt=\"Morgane Thepaut - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Morgane Thepaut<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/remi-bonjean\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/remi-bonjean\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/bonjean_remi_crcm.jpg\" alt=\"Bonjean R&#xE9;mi - Marseille Cancer Research Center - Antibody Therapeutics and Immunoblotting Team (ATI)\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">R\u00e9mi Bonjean<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/remi-lasserre\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/remi-lasserre\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/Remi-Lasserre.jpg\" alt=\"r&#xE9;mi lasserre - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">R\u00e9mi Lasserre<\/h2>\n\n<h4 class=\"wp-block-heading\">Researcher<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/remy-boisgard\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/remy-boisgard\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/boisgard_remi_crcm.jpg\" alt=\"Boisgard R&#xE9;mi - Marseille Cancer Research Center - Antibody Therapeutics and Immunoblotting Team (ATI)\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">R\u00e9my Boisgard<\/h2>\n\n<h4 class=\"wp-block-heading\">Doctoral student<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/sarah-tazekritt\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/sarah-tazekritt\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/picto-sans-image.jpg\" alt=\"Sarah Tazekritt\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Sarah Tazekritt<\/h2>\n\n<h4 class=\"wp-block-heading\">Master 2 trainee<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/timothee-chanier\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/timothee-chanier\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/Timothee-Chanier.jpg\" alt=\"Timoth&#xE9;e Chanier - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Timoth\u00e9e Chanier<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/antonoff-octavia\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/antonoff-octavia\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/Antonoff-Octavia.jpg\" alt=\"Antonoff Octavia - Antibody Therapeutics and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Antonoff Octavia<\/h2>\n\n<h4 class=\"wp-block-heading\">Lecturer<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/brigitte-kerfelec\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/brigitte-kerfelec\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/kerfelec_brigitte_crcm.jpg\" alt=\"Kerfelec Brigitte - Marseille Cancer Research Center - Therapeutic Antibodies and Immunoblotting Team (ATI)\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">Brigitte Kerfelec<\/h2>\n\n<h4 class=\"wp-block-heading\">Researcher<\/h4>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/team\/celia-torrielli\/\"><\/a><\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/team\/celia-torrielli\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/torrielli_celia_crcm.jpg\" alt=\"Torrielli C&#xE9;lia - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/a><\/figure>\n\n<h2 class=\"wp-block-heading\">C\u00e9lia Torrielli<\/h2>\n\n<h4 class=\"wp-block-heading\">Engineer<\/h4>\n\n<h2 class=\"wp-block-heading\">The Antibody Therapeutics and Immunoblotting (ATI) team explores the potential of synthetic biology applied to fundamental immunology and cancer immunotherapy.<\/h2>\n\n<p>Our team has developed solid expertise in the generation and use of single-domain antibodies, or VHHs, corresponding to the variable domain of naturally light-chain-free antibodies found in camelids. We are exploiting the possibilities offered by this technology as tools for fundamental studies, or as building blocks for the development of innovative approaches to cancer imaging and therapy.<br\/>In particular, we believe that multispecificity is a key concept for developing next-generation immune modulators, as a means of reaching wider therapeutic windows by developing intelligent conditional engagement, or as a means of avoiding leakage through antigen down-regulation. The exquisite modularity of single-domain antibodies is used to demonstrate these principles.  <\/p>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/natural-killer-cell-and-cancer-cell-equipe-anticorps-therapeutiques-et-immunociblage.jpg\" alt=\"Media natural killer cell and cancer - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h2 class=\"wp-block-heading\">The projects<\/h2>\n\n<h4 class=\"wp-block-heading\"><strong>AXIS 1: EXPLORE T CELL ACTIVATION FROM INITIATION TO RELEASE<\/strong><\/h4>\n\n<h5 class=\"wp-block-heading\"><strong>Molecular dynamics at the immunological synapse during the initiation of T cell activation :<\/strong><\/h5>\n\n<p>The binding of the T cell receptor (TCR) to its ligand triggers a cascade of molecular events, forming the immunological synapse &#8211; a specialized interface between the T cell and the antigen-presenting cell (APC) essential for T cell activation. This process involves numerous molecular players whose dynamics and distribution are tightly regulated to modulate activation signals.<\/p>\n\n<p>To explore the orchestration of T cell activation, we are developing innovative fluorescent probes based on single-domain antibodies targeting key immune receptors and lymphocyte surface molecules. Combined with advanced live-cell imaging techniques, these probes enable high-resolution analysis of the molecular choreography initiated by TCR engagement. Our aim is to uncover the mechanisms that determine the specificity, sensitivity and speed of TCR in T cell activation.  <\/p>\n\n<h5 class=\"wp-block-heading\"><strong>TCELL-CODE project: Decoding the T cell response to TCR stimulation dynamics:<\/strong><\/h5>\n\n<p>In the lymph node, T cell activation is initiated by transient interactions with antigen-presenting cells displaying the corresponding TCR ligand. The mechanisms enabling T cells to integrate multiple transient TCR stimuli, and the influence of TCR triggering dynamics (duration, frequency) on activation outcomes, remain unclear. To answer these questions, we have developed the Light-inducible T cell engager (LiTE) system, a light-controlled TCR agonist based on optogenetics. This system enables precise spatio-temporal control of TCR stimulation, mimicking the dynamics of engagement during lymphocyte activation in vivo.   <\/p>\n\n<p>The TCELL-CODE project uses LiTE to study how the dynamics of TCR stimulation shape T cell responses. Combining optogenetics, phospho-proteomics, transcriptomics and computational sciences, it offers a comprehensive analysis of TCR-triggered responses at the molecular and cellular levels. This research aims to understand how the dynamics of TCR stimulation influence T cell fate, with implications for both basic immunology and translational research. <\/p>\n\n<h4 class=\"wp-block-heading\"><strong>AXIS 2: ENGAGING EFFECTOR CELLS FOR CANCER THERAPY<\/strong><\/h4>\n\n<h5 class=\"wp-block-heading\"><strong>CARMA: Adapting CAR T cell metabolism and activation to improve therapeutic efficacy:<\/strong><\/h5>\n\n<p>Adoptive T-cell therapy using chimeric antigen receptor (CAR) technology has shown promise in the treatment of cancer, particularly hematological malignancies. However, challenges related to the persistence and functionality of CAR T cells limit their efficacy against solid tumors. Recent research highlights energy metabolism, in particular mitochondrial fitness and respiratory capacity, as key factors in CAR T cell efficacy and patient prognosis.  <\/p>\n\n<p>The CARMA project aims to develop a novel T cell activation method to produce CAR T cells with optimized metabolic profiles. Using an advanced optogenetic system, we can precisely control the dynamics and intensity of T cell stimulation to shape specific metabolic profiles with enhanced mitochondrial function. <\/p>\n\n<p>By integrating optogenetics, cell biology, metabolism and onco-immunology, CARMA aims to generate CAR T cells with improved efficacy against solid tumors. In collaboration with neuro-oncologists at the H\u00f4pital de la Timone, we are evaluating these cells in advanced preclinical models. This project has the potential to significantly advance adoptive cell immunotherapy.  <\/p>\n\n<p>In addition, we are exploring the potential of single-domain antibodies to generate multispecific CAR-T cells.<\/p>\n\n<h5 class=\"wp-block-heading\"><strong>Multispecific immune modulators :<\/strong><\/h5>\n\n<p>One of our main interests is to design effective multispecific immune cell mobilizers and modulators targeting different effector cells such as NK cells, T cells or macrophages. Their mechanisms of action and their ability to bypass any resistance mechanisms set up by tumor cells to evade their action are studied using 2D and 3D cell models in vitro, and their therapeutic efficacy in vivo in mouse models repopulated with human immune cells. <\/p>\n\n<p>The exact mechanism by which cell mobilizer architecture regulates the formation of immunological synapses, and hence the potency of cell mobilizers, remains largely unexplored. Understanding the structure-function relationships between cell mobilizer architecture and the formation and function of immunological synapses could accelerate the design of new cancer therapies. As part of a consortium comprising biophysicists specializing in the measurement of mechanical forces applied to immune receptors, the design of pattern-controlled structures including lipid bilayers, and the national pioneer of DNA origami techniques, we are harnessing the power of DNA origami approaches to design and finely test a wide variety of cellular mobilizers varying in valence, affinity, specificity, rigidity and size.  <\/p>\n\n<h4 class=\"wp-block-heading\"><strong>AXIS 3: EXPLORE INNOVATIVE TARGETED DISTRIBUTION CHANNELS<\/strong><\/h4>\n\n<p>Ideally, a therapeutic product should be present in high concentration in the tumor microenvironment to maximize its effects, while being virtually absent from the systemic circulation to avoid off-target or on-target tumor targeting. We are exploring several ways of achieving this objective through the use of single-domain antibodies. <\/p>\n\n<h5 class=\"wp-block-heading\"><strong>Oncolytic viruses (OV) :<\/strong><\/h5>\n\n<p>OVs are viruses that can infect cancer cells, causing lysis while sparing normal cells. Upon infection, tumor cells lyse while releasing danger signals leading to an inflamed tumor microenvironment more sensitive to immunotherapy. OVs can also be engineered (weaponized) to drive intratumoral secretion of cytokines, chemokines or therapeutic constructs. We are developing a program aimed at i) improving the safety of oncovirus therapy through VHH-based virus retargeting, and ii) arming the virus to induce the secretion of immunomodulators in the tumor microenvironment.     <\/p>\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n<p><strong>pH-sensitive microcapsules:<\/strong> the acidic microenvironment of tumors, resulting from glycolysis, hypoxia and insufficient blood perfusion, is a hallmark of cancer. In collaboration with a team of chemists specialized in nanoparticle generation, we aim to design novel nanocapsules targeting tumor cells via VHH surface display. Once enriched in the acidic microenvironment, the wall of these microcapsules is destabilized, leading to the conditional release of their therapeutic content, such as immune cell engageors, into the tumor microenvironment.  <\/p>\n\n<h5 class=\"wp-block-heading\"><\/h5>\n\n<p><strong>Extracellular vesicles:<\/strong> Extracellular vesicles (EVs) offer great potential for cancer therapy due to their ability to transport bioactive molecules, including RNA, proteins and drugs, to target cells with high specificity. EVs derived from engineered cells can be customized to deliver therapeutic agents or act as immune modulators. Their biocompatibility and low immunogenicity make them ideal for therapeutic applications. We are exploring the potential of single-domain antibodies to generate targeted therapeutic EVs.   <\/p>\n\n<p>More generally, we exploit the versatility of single-domain constructs to generate multispecific antibody-drug conjugates and targeted radiopharmaceuticals for cancer imaging and therapy.<\/p>\n\n<h2 class=\"wp-block-heading\">Team news<\/h2>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/the-chames-team-deciphers-the-interaction-between-immune-response-and-the-efficiency-of-immune-cell-engagers\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/Chames-News-2.jpg\" alt=\"\"\/><\/a><\/figure>\n\n<h4 class=\"wp-block-heading\"><a href=\"https:\/\/crcm-marseille.fr\/en\/scientific-publication\/the-chames-team-deciphers-the-interaction-between-immune-response-and-the-efficiency-of-immune-cell-engagers\/\">In Press: Decoupling Individual Host Response and Immune Cell Engager Cytotoxic Potency<\/a><\/h4>\n\n<p>Immune cell engagers, such as bispecific antibodies, are revolutionizing cancer immunotherapy. A new study explores how their molecular and cellular characteristics influence their efficacy, proposing an innovative model for optimizing their design. <\/p>\n\n<figure class=\"wp-block-image\"><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/major-funding-for-the-therapeutic-antibodies-and-immunoblotting-team-chames-group\/\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/Chames-News-1.jpg\" alt=\"\"\/><\/a><\/figure>\n\n<h4 class=\"wp-block-heading\"><a href=\"https:\/\/crcm-marseille.fr\/en\/team-chames\/major-funding-for-the-therapeutic-antibodies-and-immunoblotting-team-chames-group\/\">Major funding for the Therapeutic Antibodies and Immunoblotting team<\/a><\/h4>\n\n<p>The ATI team celebrates a double victory with prestigious funding for its innovative immunotherapy projects.<\/p>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/toutes-les-categories\/equipe-nunes-devillier\/ils-ont-fait-partie-de-lequipe\/\" target=\"_blank\" rel=\"noreferrer noopener\">All our news<\/a><\/p>\n\n<h2 class=\"wp-block-heading\">front-page publications<\/h2>\n\n<p>05\/2024<\/p>\n\n<p><a href=\"https:\/\/pubs.rsc.org\/en\/content\/articlelanding\/2024\/lc\/d4lc00011k\" target=\"_blank\" rel=\"noreferrer noopener\">Antigen density and applied force control enrichment of nanobody-expressing yeast cells in microfluidics. <\/a><\/p>\n\n<p>Sanicas M, Torro R, Limozin L, Chames P.<\/p>\n\n<p>06\/2023<\/p>\n\n<p><a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2023.1200652\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies. <\/a><\/p>\n\n<p>Benloucif A, Meyer D, Balasse L, Goubard A, Danner L, Bouhlel A, Castellano R, Guillet B, Chames P*, Kerfelec B*.<\/p>\n\n<p>08\/2022<\/p>\n\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41589-022-01050-2\" target=\"_blank\" rel=\"noreferrer noopener\">Nanobody-based sensors reveal a high proportion of mGlu heterodimers in the brain. <\/a><\/p>\n\n<p>Meng J, Xu C, Lafon PA, Roux S, Mathieu M, Zhou R, Scholler P, Blanc E, Becker JAJ, Le Merrer J, Gonz\u00e1lez-Maeso J, Chames P, Liu J, Pin JP, Rondard P.<\/p>\n\n<p>08\/2021<\/p>\n\n<p><a href=\"https:\/\/www.pnas.org\/doi\/full\/10.1073\/pnas.2105848118\" target=\"_blank\" rel=\"noreferrer noopener\">A nanobody activating metabotropic glutamate receptor 4 discriminates between homo- and heterodimers. <\/a><\/p>\n\n<p>Haubrich J, Font J, Quast RB, Goupil-Lamy A, Scholler P, Nevoltris D, Acher F, Chames P, Rondard P, Pr\u00e9zeau L, Pin JP.<\/p>\n\n<p>12\/2017<\/p>\n\n<p><a href=\"https:\/\/www.nature.com\/articles\/s41467-017-01489-1\" target=\"_blank\" rel=\"noreferrer noopener\">Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor homodimers in contextual fear consolidation. <\/a><\/p>\n\n<p>Scholler P#, Nelvoltris D#, de Bundel D, Bossi S, Moreno-Delgado D, Rovira X, Moller TC, El Moustaine D, Mathieu M, Blanc E, McLean H, Dupuis E, Mathis G, Trinquet E, Daniel H, Valjent E, Baty D, Chames P*, Rondard P* and Pin JP. *corresponding authors <\/p>\n\n<p>02\/2015<\/p>\n\n<p><a href=\"https:\/\/doi.org\/10.1021\/nn505752u\" target=\"_blank\" rel=\"noreferrer noopener\">Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR\/ErbB2 predimers. <\/a><\/p>\n\n<p>Nevoltris D, Lombard B, Dupuis E, Mathis G, Chames P*, Baty D*. *co-senior author <\/p>\n\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=chames+p&amp;sort=date\" target=\"_blank\" rel=\"noreferrer noopener\">All our publications<\/a><\/p>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/09\/forme-gris-equipe-gauche-crcm.png\" alt=\"Grey form equpe CRCM\"\/><\/figure>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/09\/formes-equipe-droite-crcm.png\" alt=\"Form CRCM team\"\/><\/figure>\n\n<h2 class=\"wp-block-heading\">Labels, Funding and Partners<\/h2>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.e-cancer.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/anr.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.inserm.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cnrs.fr\/fr\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.univ-amu.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.e-cancer.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/anr.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.inserm.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cnrs.fr\/fr\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.univ-amu.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.e-cancer.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/anr.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.inserm.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.cnrs.fr\/fr\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a><\/li>\n<\/ul>\n\n<p>Alumni<\/p>\n\n<p>Like others, they were part of the team.<br\/>Thanks to all those who contributed to CRCM&#8217;s excellence and impact.<\/p>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/nelvotris_damien_crcm.jpg\" alt=\"Nelvotris Damien - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Damien Nelvotris<\/h5>\n\n<h5 class=\"wp-block-heading\">Team leader antibody, AC Immune, Switzerland<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/colazet_magali_crcm.jpg\" alt=\"Colazet Magali - Antibody Therapeutics and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Magali Colazet<\/h5>\n\n<h5 class=\"wp-block-heading\">R&amp;D scientist, Imckeck Therapeutics<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/desrumeaux_klervi_crcm.jpg\" alt=\"Desrumeaux Klervi - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Klervi Desrumeaux<\/h5>\n\n<h5 class=\"wp-block-heading\">Group head Antibody discovery, SANOFI<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/turini_marc_crcm.jpg\" alt=\"Turini Marc - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Marc Turini<\/h5>\n\n<h5 class=\"wp-block-heading\">Project leader, Beckman Coulter<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/di_palma_morgane_crcm.jpg\" alt=\"Di Palma Morgane - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Morgane Di Palma<\/h5>\n\n<h5 class=\"wp-block-heading\">Post doctoral student, Univ Bern<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/del_bano_joanie_crcm.jpg\" alt=\"Del Bano Joanie - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Joanie del Bano<\/h5>\n\n<h5 class=\"wp-block-heading\">Chief Executive Officer, THELONIUS MIND<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/cohen-romy-crcm.jpg\" alt=\"Cohen Romy - Antibody Therapeutics and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Romy COHEN<\/h5>\n\n<h5 class=\"wp-block-heading\">Scientist, Vect-Horus S.A.S.<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/sanicas_merlin_crcm.jpg\" alt=\"Sanicas Merlin - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Merlin sanicas<\/h5>\n\n<h5 class=\"wp-block-heading\">Research Scientist, Immunocore, UK<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/12\/adeline_raynaud_crcm.jpg\" alt=\"Adeline Raynaud - Therapeutic Antibodies and Immunoblotting Team (ATI) - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Adeline Raynaud<\/h5>\n\n<h5 class=\"wp-block-heading\">Scientist, Veracyte<br\/>PhD student<\/h5>\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2025\/01\/termine_elise_crcm.jpg\" alt=\"Termine Elise - alumni of the Single-Domain Antibodies platform - - Antibodies and Immunoblotting (ATI) Team - CRCM\"\/><\/figure>\n\n<h5 class=\"wp-block-heading\">Elise Termine<\/h5>\n\n<h5 class=\"wp-block-heading\">Engineer<\/h5>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/en\/\">Intranet connection<\/a><br\/><a href=\"https:\/\/crcm-marseille.fr\/en\/directory\/\">Directory<\/a><br\/><a href=\"https:\/\/crcm-marseille.fr\/en\/\">About IPC<\/a><br\/><a href=\"https:\/\/crcm-marseille.fr\/en\/news\/\">News<\/a><br\/><a href=\"https:\/\/crcm-marseille.fr\/evenements\/\">Events<\/a><br\/><a href=\"https:\/\/crcm-marseille.fr\/en\/\">Legal notice<\/a><br\/><a href=\"https:\/\/crcm-marseille.fr\/en\/\">Privacy policy<\/a><\/p>\n\n<h3 class=\"wp-block-heading\">Marseille Cancer Research Center<\/h3>\n\n<p>27 Bd Le\u00ef Roure, CS 30059<br\/>13273 Marseille Cedex 09<\/p>\n\n<p>Tel: 04 86 97 72 00<\/p>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/en\/\">Contact us<br\/>How to get here<\/a><\/p>\n\n<p>Follow us<\/p>\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/x.com\/crcm_marseille\" target=\"_blank\" rel=\"noreferrer noopener\">X<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.youtube.com\/@CRCM-marseille\" target=\"_blank\" rel=\"noreferrer noopener\">YouTube<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.linkedin.com\/company\/crcm-marseille\/\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/bsky.app\/profile\/crcm.bsky.social\" target=\"_blank\" rel=\"noreferrer noopener\">Bluesky<\/a><\/li>\n<\/ul>\n\n<p><a href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunoblotting-team-ati-ohio-department\/\"><\/a><\/p>\n\n<p>www.crcm-marseille.fr \u00a92024 | All rights reserved &#8211; Created by <a href=\"https:\/\/yesss-communication.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Yesss Communication<\/a> &amp; <a href=\"https:\/\/www.bioself-communication.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Bioself<\/a><\/p>\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antibody Therapeutics and Immunoblotting (ATI) Luminy Patrick Chames Team manager R\u00e9my Boisgard Doctoral student<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":5900,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_tec_requires_first_save":true,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","footnotes":""},"class_list":["post-5902","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Antibody Therapeutics and Immunotargeting | CRCM<\/title>\n<meta name=\"description\" content=\"CRCM Team - Antibody Therapeutics and Immunotargeting (ATI) Team - OHIO Department - Patrick Chames&#039; team...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibody Therapeutics and Immunotargeting | CRCM\" \/>\n<meta property=\"og:description\" content=\"CRCM Team - Antibody Therapeutics and Immunotargeting (ATI) Team - OHIO Department - Patrick Chames&#039; team...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/\" \/>\n<meta property=\"og:site_name\" content=\"CRCM\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-23T12:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/\",\"url\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/\",\"name\":\"Antibody Therapeutics and Immunotargeting | CRCM\",\"isPartOf\":{\"@id\":\"https:\/\/crcm-marseille.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847\",\"datePublished\":\"2024-12-04T14:03:40+00:00\",\"dateModified\":\"2025-06-23T12:04:23+00:00\",\"description\":\"CRCM Team - Antibody Therapeutics and Immunotargeting (ATI) Team - OHIO Department - Patrick Chames' team...\",\"breadcrumb\":{\"@id\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#primaryimage\",\"url\":\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847\",\"contentUrl\":\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/crcm-marseille.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OHIO Department\",\"item\":\"https:\/\/crcm-marseille.fr\/en\/ohio-department\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Antibody Therapeutics and Immunotargeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/crcm-marseille.fr\/en\/#website\",\"url\":\"https:\/\/crcm-marseille.fr\/en\/\",\"name\":\"CRCM\",\"description\":\"Marseille Cancer Research Center\",\"publisher\":{\"@id\":\"https:\/\/crcm-marseille.fr\/en\/#organization\"},\"alternateName\":\"Centre de recherche en canc\u00e9rologie de Marseille\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/crcm-marseille.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/crcm-marseille.fr\/en\/#organization\",\"name\":\"CRCM\",\"alternateName\":\"Centre de Recherche en Canc\u00e9rologie de Marseille\",\"url\":\"https:\/\/crcm-marseille.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/crcm-marseille.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-crcm.png\",\"contentUrl\":\"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-crcm.png\",\"width\":11811,\"height\":7171,\"caption\":\"CRCM\"},\"image\":{\"@id\":\"https:\/\/crcm-marseille.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.youtube.com\/@CRCM-marseille\",\"https:\/\/www.linkedin.com\/company\/crcm-marseille\/\",\"https:\/\/bsky.app\/profile\/crcm.bsky.social\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibody Therapeutics and Immunotargeting | CRCM","description":"CRCM Team - Antibody Therapeutics and Immunotargeting (ATI) Team - OHIO Department - Patrick Chames' team...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/","og_locale":"en_US","og_type":"article","og_title":"Antibody Therapeutics and Immunotargeting | CRCM","og_description":"CRCM Team - Antibody Therapeutics and Immunotargeting (ATI) Team - OHIO Department - Patrick Chames' team...","og_url":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/","og_site_name":"CRCM","article_modified_time":"2025-06-23T12:04:23+00:00","og_image":[{"url":"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/","url":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/","name":"Antibody Therapeutics and Immunotargeting | CRCM","isPartOf":{"@id":"https:\/\/crcm-marseille.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#primaryimage"},"image":{"@id":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#primaryimage"},"thumbnailUrl":"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847","datePublished":"2024-12-04T14:03:40+00:00","dateModified":"2025-06-23T12:04:23+00:00","description":"CRCM Team - Antibody Therapeutics and Immunotargeting (ATI) Team - OHIO Department - Patrick Chames' team...","breadcrumb":{"@id":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#primaryimage","url":"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847","contentUrl":"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-centre-de-recherche-en-cancerologie-de-marseille-crcm.webp#847"},{"@type":"BreadcrumbList","@id":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/antibody-therapeutics-and-immunotargeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/crcm-marseille.fr\/en\/"},{"@type":"ListItem","position":2,"name":"OHIO Department","item":"https:\/\/crcm-marseille.fr\/en\/ohio-department\/"},{"@type":"ListItem","position":3,"name":"Antibody Therapeutics and Immunotargeting"}]},{"@type":"WebSite","@id":"https:\/\/crcm-marseille.fr\/en\/#website","url":"https:\/\/crcm-marseille.fr\/en\/","name":"CRCM","description":"Marseille Cancer Research Center","publisher":{"@id":"https:\/\/crcm-marseille.fr\/en\/#organization"},"alternateName":"Centre de recherche en canc\u00e9rologie de Marseille","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/crcm-marseille.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/crcm-marseille.fr\/en\/#organization","name":"CRCM","alternateName":"Centre de Recherche en Canc\u00e9rologie de Marseille","url":"https:\/\/crcm-marseille.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/crcm-marseille.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-crcm.png","contentUrl":"https:\/\/crcm-marseille.fr\/wp-content\/uploads\/2024\/10\/logo-crcm.png","width":11811,"height":7171,"caption":"CRCM"},"image":{"@id":"https:\/\/crcm-marseille.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@CRCM-marseille","https:\/\/www.linkedin.com\/company\/crcm-marseille\/","https:\/\/bsky.app\/profile\/crcm.bsky.social"]}]}},"_links":{"self":[{"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/pages\/5902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/comments?post=5902"}],"version-history":[{"count":0,"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/pages\/5902\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/pages\/5900"}],"wp:attachment":[{"href":"https:\/\/crcm-marseille.fr\/en\/wp-json\/wp\/v2\/media?parent=5902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}